New business partnership between Otsuka Pharmaceutical and digital health VR technology developer Jolly Good


Deal Worth Potential 5 Billion Yen for Virtual Reality Health Market

First stage: the social rehabilitation of people suffering from schizophrenia

TOKYO, February 1, 2022 /PRNewswire/ — In an effort to create a regional cooperative mental health platform, Jolly Good Inc. (Chuo-ku, Tokyo; CEO: Kensuke Joji) and Otsuka Pharmaceutical Co., Ltd. (Chiyoda-ku, Tokyo; Chairman and Deputy Director: Makoto Inoue) have signed an agreement for the joint development and sale of proprietary products in Japan for a VR social skills training company (“SST VR”). Including an upfront payment of 300 million yen from Otsuka Pharmaceutical to Jolly Good, as well as reimbursement of development costs and royalties, the deal is worthwhile. 5 billion yen.

Reports(*1) cited the combined use of drug therapy and SST as a psychotherapeutic method that reduces recurrence rates of mental disorders, and Jolly Good’s immersive SST VR is expected to help patients focus better and improve efficiency. dr. Ayako Kaniepsychiatry specialist and senior medical supervisor, will be responsible for producing content for Jolly Good’s VR business.


This agreement, which establishes a partnership between advanced VR video technology manufacturer Jolly Good and Otsuka Pharmaceutical, which has extensive knowledge, experience and network in psychiatry, will facilitate the development of an SST that uses VR for a variety of mental disorders and the creation of new platforms in the future. Jolly Good has already deployed SST VR for developmental disabilities in more than 200 hospitals, clinics, social support centers and similar facilities across Japan.

Through this venture, Jolly Good will provide the necessary VR glasses and tablets and produce SST VR content for a range of scenarios in collaboration with Otsuka Pharmaceutical. Otsuka Pharmaceutical will compensate Jolly Good for sales activities to healthcare facilities and will pay Jolly Good royalties based on sales. This partnership is Otsuka Pharmaceutical’s first commercial partnership inmthe mental health industry using virtual reality. Both companies aim to build from Japan the largest virtual reality company in mental health care.

*1: Hogarty GE et al. : Arch Gen Psychiatry 43: 633-642, 1986

dr. Ayako KanieSenior Medical Supervisor, Jolly Good Inc.

Along with symptom suppression, “self-actualization beyond therapy” becomes an additional goal of therapy for the treatment of mental disorders such as schizophrenia. Currently, there is a severe shortage of people who have the social skills training and other qualities needed to provide ‘psychosocial therapy’.

Our VR content development benefits from broad involvement of psychiatrists in product design and aims to improve and expand the possibilities of providing psychosocial therapy according to medical theory. Virtual reality allows patients to practice in a near-real environment and will set them up for success in real-life situations. This pursuit will pave the way for everyone to acquire life skills.

Comments from business leaders>

Kensuke JojiCEO, Jolly Good

The high-precision medical virtual reality system developed by Jolly Good has been highly praised in many areas of the healthcare industry, including medical personnel training, patient rehabilitation, and people social rehabilitation training. disabled or mentally ill.
This partnership will see the convergence of Otsuka Pharmaceutical’s vast experience and sales network, enabling the enhancement and expansion of our SST VR. It gives me a great sense of joy and mission that we are working with regional cooperative platforms nationwide to support the social rehabilitation of people with mental disorders. Through this partnership, Jolly Good will develop a social contribution platform powered by VR technology while further growing its business.

Makoto Inouechairman and managing director, Otsuka Pharmaceutical

Otsuka Pharmaceutical conducts its global pharmaceutical business to treat mental and neurological disorders, a key focus for the company. In recent years, advances in technology have placed increasing importance not only on medication, but also on supporting daily living, which includes everything from prevention to caregiving. Alongside using digital technologies that will go into creating a new business model, we will work with Jolly Good, which supports healthcare through cutting-edge VR video technologies, to build a platform to facilitate reintegration social among people with mental or neurological disorders.

Guided by our corporate philosophy “Otsuka people create new products for better health around the world”, Otsuka Pharmaceutical develops diversified business as a global healthcare company focusing on two core businesses . These are the pharmaceutical business, which focuses on the diagnosis and treatment of disease, and the nutraceutical business, which supports the maintenance and improvement of daily health.

Jolly Good is a medical technology company that develops high-precision VR solutions and AI-based medical and social services that analyze user behavior in the VR space. Using technologies such as virtual reality and AI, we accelerate human growth and social reintegration in medical education, disability support, mental illness treatment, etc., and service development to support the evolution of medical care and find purpose. in life, in collaboration with various research institutions and companies.

Jolly Good is looking for business partners to help jointly develop, research and sell digital therapies in the areas of mental illness and lifestyle diseases.

Copyright © acrofan All rights reserved

Source link


Comments are closed.